- Patient Information:
Details with Side Effects
There is no known antidote for ARIXTRA. Overdose of ARIXTRA may lead to hemorrhagic complications. Discontinue treatment and initiate appropriate therapy if bleeding complications associated with overdosage occur.
Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of ARIXTRA can increase by 20% during hemodialysis.
ARIXTRA is contraindicated in the following conditions:
- Severe renal impairment (creatinine clearance [CrCl] < 30 mL/min). [See WARNINGS AND PRECAUTIONS and Use in Specific Populations]
- Active major bleeding.
- Bacterial endocarditis.
- Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.
- Body weight < 50 kg (venous thromboembolism [VTE] prophylaxis only) [see WARNINGS AND PRECAUTIONS].
- History of serious hypersensitivity reaction (e.g., angioedema, anaphylactoid/anaphylactic reactions) to ARIXTRA.
Last reviewed on RxList: 9/26/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Arixtra Information
Arixtra - User Reviews
Arixtra User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.